Bristol-Myers Squibb Co (BMY) reported better-than-expected financial results for the third quarter of fiscal 2025. The company's earnings per share (EPS) reached $1.63, surpassing Wall Street's consensus estimate of $1.52 by $0.11. Revenue also exceeded expectations, coming in at $12.2 billion compared to the anticipated $11.9 billion.
This update provides insight into Bristol-Myers Squibb's operational performance and financial health. The company's strong results may suggest robust business fundamentals.
Bristol-Myers Squibb, headquartered in Princeton, New Jersey, is a leading player in the pharmaceuticals industry, focusing on the discovery, development, and delivery of transformational medicines for serious diseases. Its growth portfolio includes well-known products such as Opdivo, Yervoy, and Reblozyl, among others.
The company will host an earnings conference call at BMO to discuss these results and provide additional commentary on business performance. Investors can look forward to further insights as the company prepares for its next earnings report, scheduled for October 28, 2026, with EPS and revenue estimates of $1.5645 and $11.1 billion, respectively.